{
    "clinical_study": {
        "@rank": "58566", 
        "arm_group": {
            "arm_group_label": "Miravirsen sodium", 
            "arm_group_type": "Experimental", 
            "description": "Miravirsen will be dosed as single subcutaneous injections.  Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this open-label study is to assess the safety, antiviral activity, and\n      pharmacokinetics of 9 subcutaneous injections of miravirsen monotherapy (5 weekly doses over\n      5 weeks, followed by a further 4 doses once every other week over 7 weeks) over a total of\n      12 weeks of treatment.  The subjects enrolled in this study are chronically infected with\n      HCV genotype 1 and are null responders to treatment with peg IFN\u03b1/RBV therapy."
        }, 
        "brief_title": "Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of chronic hepatitis C\n\n          -  HCV genotype 1\n\n          -  BMI 18-38 kg/m2\n\n          -  Null responder to pegylated interferon alpha and ribavirin\n\n        Exclusion Criteria:\n\n          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\n          -  Significant liver disease in addition to hepatitis C\n\n          -  Decompensated liver disease medical history or current clinical features\n\n          -  Histologic evidence of hepatic cirrhosis\n\n          -  Concurrent clinically significant medical diagnosis (other than CHC)\n\n          -  Concurrent social conditions (e.g. drugs of abuse, alcohol excess, poor living\n             accommodation)\n\n          -  Clinically significant illness within 30 days preceding entry into the study\n\n          -  Participated in an investigational drug study within 30 days or 5 half-lives,\n             whichever is longer, prior to the start of study medication\n\n          -  History of clinically significant allergic drug reactions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727934", 
            "org_study_id": "SPC3649-207"
        }, 
        "intervention": {
            "arm_group_label": "Miravirsen sodium", 
            "description": "Subcutaneous injection", 
            "intervention_name": "Miravirsen sodium", 
            "intervention_type": "Drug", 
            "other_name": "SPC3649"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Antisense", 
            "miR-122 antagonist", 
            "host factor", 
            "Chronic hepatitis C", 
            "Hepatitis C"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Juan", 
                    "country": "Puerto Rico", 
                    "zip": "00927"
                }, 
                "name": "Fundacion de Investigation de Diego"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection", 
        "other_outcome": [
            {
                "description": "The miR-122 seed sites in HCV RNA from subjects at baseline and following viral breakthrough or relapse will be subjected to genotypic sequence analysis.", 
                "measure": "Viral resistance analysis at baseline and throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "60 weeks"
            }, 
            {
                "description": "Plasma PK for miravirsen levels will be determined for up to 2 hours post-dose on Day 1, up to 24 hours post-dose on Days 29 and 84, and pre-dose for all other treatment period visits.  Additionally, plasma PK will be evaluated at all follow-up visits through Week 28.", 
                "measure": "Plasma pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Urine pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours post-dose on Day 29 and Day 84"
            }
        ], 
        "overall_official": {
            "affiliation": "Fundacion de Investgacion de Diego", 
            "last_name": "Maribel Rodriguez-Torres, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects with sustained virological response 24 weeks after the end of therapy.", 
            "safety_issue": "No", 
            "time_frame": "36 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects with a sustained virological response 12 and 48 weeks after the end of therapy.", 
                "safety_issue": "No", 
                "time_frame": "60 weeks"
            }, 
            {
                "measure": "The proportion of subjects with undetectable HCV RNA levels at the end of treatment.", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in HCV RNA levels from baseline throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "60 weeks"
            }, 
            {
                "measure": "The proportion of subjects who experience virological failure throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "60 weeks"
            }, 
            {
                "measure": "Safety will be assessed by evaluation of adverse events, physical examinations, vital signs, 12-lead ECGs, and laboratory assessments (clinical chemistry, hematology, urinalysis).", 
                "safety_issue": "Yes", 
                "time_frame": "60 weeks"
            }
        ], 
        "source": "Santaris Pharma A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santaris Pharma A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}